Purpose-built for personalized precision

Uncover residual disease like never before with exquisite MRD detection sensitivity.

Exquisite sensitivity

Haystack MRD™

Minimal residual disease (MRD) testing demands the most sensitive ctDNA detection. Haystack MRD is a tumor-informed, next-generation MRD test that detects ultralow levels of circulating tumor DNA (ctDNA) to uncover residual disease after definitive surgery.

Residual disease detection

Go beyond standard risk assessment for adjuvant chemotherapy guidance to confidently treat the right person at the right time.

Treatment response monitoring

Track ctDNA levels during adjuvant chemotherapy or second-line therapy to monitor treatment response and acquired resistance.

Disease recurrence surveillance

Detect molecular recurrence with greater lead time before clinical relapse.

Transformative precision

Dive deeper

Haystack Oncology was founded to dramatically improve patient outcomes by helping doctors optimize treatment strategies using transformative precision oncology. Learn how we support clinicians and biopharma in our mission by providing better MRD testing for better clinical management and therapeutic development.

The difference

Why Haystack MRD

Confident MRD results

Our deep knowledge of precision science optimizes ctDNA testing to deliver the data you need to make confident treatment decisions.

Transformative technology

Built by giants

Haystack Oncology was founded by pioneers in blood-based cancer diagnostics who were the first to envision a revolution in patient care made possible by groundbreaking molecular methods.

Packed with the power of Quest

Haystack MRD offers end-to-end MRD test reliability, powered by Quest Diagnostics credentialed staff, labs, logistics, service, reporting, and technology. Plus, the transition between Haystack MRD and Quest’s other advanced oncology testing is seamless for easier, more streamlined patient care. Visit questdiagnostics.com to learn more.

Haystack MRD

In the news

Find out what’s happening at Haystack Oncology and stay up-to-date with industry news.

Exquisite MRD test sensitivity at ESMO 2024 in Barcelona

September 3, 2024

Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual meeting stands as the cornerstone of the cancer research community, serving as a gathering point for scientists, clinicians, healthcare practitioners, survivors, patients, and advocates.

Haystack Oncology and Université de Montréal’s affiliated hospital research centre, the CRCHUM, to Deploy Haystack MRD™ Technology in Research Study for Metastatic Colorectal Cancer

July 29, 2024

Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of best-in-class personalized MRD technology (Haystack MRD™), has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

July 18, 2024